Sponsor of the Day:
Jerkmate
https://www.cancernetwork.com/view/this-week-in-oncology-real-world-nsclc-care-and-aacr-2026-updates
This Week in Oncology: Real-World NSCLC Care and AACR 2026 Updates | CancerNetwork
Apr 28, 2026 - Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases such as NSCLC and oral premalignant lesions.
real worldaacr 2026weekoncologynsclc
https://www.cancernetwork.com/authors/camelia-dobrea-md-phd
Camelia Dobrea, MD, PhD | Authors | CancerNetwork
md phdauthors cancernetworkcamelia
https://www.cancernetwork.com/authors/diane-simeone-md
Diane Simeone, MD | Authors | CancerNetwork
authors cancernetworkdianesimeonemd
https://www.cancernetwork.com/view/rising-incidence-trial-enrollment-and-other-key-breast-cancer-challenges
Rising Incidence, Trial Enrollment, and Other Key Breast Cancer Challenges | CancerNetwork
Young patients with breast cancer should always aim to advocate for themselves, said Shari Goldfarb, MD.
rising incidencebreast cancertrialenrollmentkey
https://www.cancernetwork.com/view/cd39-pd-l1-inhibition-may-improve-pcr-rate-in-resectable-nsclc
CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC | CancerNetwork
Apr 24, 2026 - Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.
pd l1may improveinhibitionpcrrate
https://www.cancernetwork.com/authors/steven-bialick-do
Steven Bialick, DO | Authors | CancerNetwork
authors cancernetworksteven
https://www.cancernetwork.com/clinical/cervical-cancer
Cervical Cancer | Clinical | CancerNetwork
cervical cancerclinicalcancernetwork
https://www.cancernetwork.com/clinical/colorectal-cancer
Colorectal Cancer | Clinical | CancerNetwork
colorectal cancerclinicalcancernetwork
https://www.cancernetwork.com/view/duvelisib-shows-significant-activity-in-r-r-peripheral-t-cell-lymphoma
Duvelisib Shows Significant Activity in R/R Peripheral T-Cell Lymphoma | CancerNetwork
Apr 28, 2026 - A total of 48.0% of patients treated with duvelisib experienced a response, 33.3% of whom experienced a complete response.
shows significantcell lymphomaactivityr
https://www.cancernetwork.com/
CancerNetwork - Oncology News and Clinical Expertise
oncology newsclinical expertisecancernetwork
https://www.cancernetwork.com/around-the-practice
Around the Practice | CancerNetwork
aroundpracticecancernetwork
https://www.cancernetwork.com/authors/chris-ryan
Chris Ryan | Authors | CancerNetwork
chris ryanauthors cancernetwork
https://www.cancernetwork.com/authors/oncology-staff
ONCOLOGY Staff | Authors | CancerNetwork
authors cancernetworkoncologystaff
https://www.cancernetwork.com/about
About Us | CancerNetwork
About Us | CancerNetwork
uscancernetwork
https://www.cancernetwork.com/view/litespark-012-trial-does-not-meet-primary-end-point-for-advanced-rcc-group
LITESPARK-012 Trial Does Not Meet Primary End Point for Advanced RCC Group | CancerNetwork
Apr 21, 2026 - The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.
end point012trialmeetprimary
https://www.cancernetwork.com/authors/mu-taz-dreidi-phd-rn
Mu’taz Dreidi, PhD, RN | Authors | CancerNetwork
phd rnauthors cancernetwork
https://www.cancernetwork.com/view/new-frontiers-in-adjuvant-care-evaluating-elacestrant-in-the-elegant-trial
New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial | CancerNetwork
Apr 24, 2026 - Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.
new frontiersadjuvantcareevaluatingelegant